Provided by Tiger Trade Technology Pte. Ltd.

Jupiter Neurosciences

6.20
+1.0319.92%
Post-market: 6.12-0.0800-1.29%19:59 EDT
Volume:52.41M
Turnover:445.04M
Market Cap:4.77M
PE:-0.33
High:11.20
Open:8.25
Low:5.50
Close:5.17
52wk High:137.96
52wk Low:4.56
Shares:770.10K
Float Shares:533.80K
Volume Ratio:1,111.30
T/O Rate:9817.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.7000
EPS(LYR):-18.7500
ROE:-1888.70%
ROA:-159.56%
PB:-13.05
PE(LYR):-0.33

Loading ...

US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada

MT Newswires Live
·
Yesterday

Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?

TIPRANKS
·
Yesterday

Jupiter Neurosciences Prices USD 2 Million Registered Direct Offering of 307,692 Shares

Reuters
·
Yesterday

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

THOMSON REUTERS
·
Yesterday

NASDAQ Trade Halt Volatility Trading Pause at 10:02 Am

Reuters
·
Aug 21

Jupiter Neurosciences FY26 Q2 Net Loss Widens 0.95% to $2.27 Million; Revenue Totals $24,245

Reuters
·
Aug 15

Jupiter Neurosciences Inc trading halted, news pending

TIPRANKS
·
Aug 07

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Aug 07

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

THOMSON REUTERS
·
Aug 05

Jupiter Neurosciences Raises Capital Through Equity Offering

TIPRANKS
·
Jul 29

Jupiter Neurosciences Sells 11,470,000 Shares to Yorkville for About $3.6 Million in Unregistered Offering

Reuters
·
Jul 29

Jupiter Neurosciences Held Annual Shareholder Meeting, with 59% of Shares Represented

Reuters
·
Jul 27

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

TIPRANKS
·
Jul 23

Jupiter Neurosciences Director Andrew Jon Cutler Files Initial Beneficial Ownership Statement

Reuters
·
Jul 23

Jupiter Neurosciences Licenses ALA-002 for U.S. Development

TIPRANKS
·
Jul 22

Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal

TIPRANKS
·
Jul 22

Jupiter Neurosciences (nasdaq: Juns) Signs Definitive Agreement for Exclusive U.S. Rights to Ala-002 in Transaction Valued at up to $100 Million

THOMSON REUTERS
·
Jul 21

Jupiter Neurosciences - Royalty of 3% of Net Sales After Third Commercialization Milestone

THOMSON REUTERS
·
Jul 21

Jupiter Neurosciences - Deal Valued at up to $100 Mln Including Milestone Payments

THOMSON REUTERS
·
Jul 21

Pharmala Licenses Exclusive US Rights to Ala-002 to Jupiter Neurosciences for up to Us$100 Million

Reuters
·
Jul 21